drugset / Trial / NCT00558298
A Long Term Study of Safety for Long Acting Injectable Risperidone in Patients With Schizophrenia or Schizoaffective Disorder.
Non-randomizedOpen-labelTreatment
Summary
The purpose of this study is to document the long-term safety of 25, 50 or 75 mg long-acting injectable risperidone given via injection to the gluteal muscle every 2 weeks to patients with schizophrenia or schizoaffective disorder.
Timeline
- Start
- 2000-02
- Primary completion
- —
- Completion
- 2005-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Risperidone | Other / unclassified | 25 mg | Intramuscular |
| Subject | Risperidone | Other / unclassified | 50 mg | Intramuscular |
| Subject | Risperidone | Other / unclassified | 75 mg | Intramuscular |